# A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

> **NCT06150014** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 88 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Placebo
- **DRUG:** TQA3605 tablets
- **DRUG:** Entecavir dispersible tablets
- **DRUG:** Tenofovir disoproxil fumarate tablet
- **DRUG:** Tenofovir alafenamide fumarate tablet

## Key facts

- **NCT ID:** NCT06150014
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2025-12
- **Final completion:** 2026-09
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150014, "A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06150014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*